SCHEDULE: RA Capital Adjusts VOR Pharma Stake

RA Capital Management, L.P. and its affiliates have amended their Schedule 13D filing to report changes in beneficial ownership of VOR BIOPHARMA INC. common stock.

Summary

• RA Capital Management, L.P. and its affiliates (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13D regarding their beneficial ownership of VOR BIOPHARMA INC. common stock.
• The filing reports an adjustment to their holdings due to the exercise of pre-funded warrants.
• As of July 16, 2026, the Fund exercised pre-funded warrants to purchase 2,100,000 shares of common stock.
• The exercise resulted in the withholding of 213 shares for the exercise price, and the issuance of 2,099,787 shares to the Fund.
• The Reporting Persons collectively beneficially own 12,937,855 shares, representing 19.9% of the class of securities.
• This percentage is based on 54,185,582 shares outstanding as of May 5, 2026, plus the newly issued shares from warrant exercises, and giving effect to other exercisable warrants and stock options within 60 days.
• Andrew Levin resigned from the Board of Directors of VOR BIOPHARMA INC. effective July 6, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reflecting a regulatory update on beneficial ownership changes due to warrant exercises and a board resignation, rather than new operational or financial performance data.

Positives

• RA Capital has increased its direct holdings through the exercise of pre-funded warrants, indicating continued investment and belief in the company.
• The exercise of warrants, even on a cashless basis, results in a net increase of nearly 2.1 million shares for the Fund.
• The Reporting Persons maintain a significant stake (19.9%) in the company, suggesting ongoing strategic interest.

Negatives

• The exercise of pre-funded warrants on a cashless basis means the company withheld shares to cover the exercise price, reducing the net shares issued to the Fund.
• The Pre-Funded Warrant Beneficial Ownership Blocker limits the Fund's ability to exercise further warrants if it would exceed 19.99% ownership, capping potential future increases through these instruments.

Risks

• The Pre-Funded Warrant Beneficial Ownership Blocker may prevent further exercise of warrants if beneficial ownership exceeds 19.99%, limiting the Fund's ability to increase its stake via this mechanism.
• The resignation of Andrew Levin from the Board of Directors could signal internal changes or strategic shifts that may impact the company's direction.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from management regarding future performance. However, the exercise of warrants indicates a continued investment interest.

Industry Context

StockSavvy.ai notes that RA Capital Management is a prominent activist investor and venture capital firm often involved in biotechnology and healthcare companies. Their filings, particularly Schedule 13D amendments, typically signal active engagement and potential strategic influence over the companies they invest in.

Management Changes

Stakeholder Impact

• Shareholders: The increase in RA Capital's stake and the resignation of a director may influence market perception and future strategic decisions, potentially impacting share value.
• Board of Directors: The resignation of Andrew Levin necessitates a potential replacement, which could alter the board's composition and dynamics.
• Management: May face increased engagement or proposals from RA Capital regarding company strategy and operations.

Next Steps

• The Reporting Persons will continue to monitor the Issuer's business and may engage in discussions with management and the Board of Directors.
• Further actions by the Reporting Persons could include acquiring additional securities, disposing of securities, or proposing strategic changes.

Key Dates

Keywords

VOR BIOPHARMA INC., RA Capital Management, Schedule 13D, Beneficial Ownership, Warrants, Stock Options, Board of Directors, SEC Filing